Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis

OncoImmunology

Volumn 6, Issue 2, 2017, Pages

  Putz, Eva M ^a   Guillerey, Camille ^a,b   Kos, Kevin ^a   Stannard, Kimberley ^a   Miles, Kim ^a   Delconte, Rebecca B ^c,d   Takeda, Kazuyoshi ^e   Nicholson, Sandra E ^c,d   Huntington, Nicholas D ^c,d   Smyth, Mark J ^a,b  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer; cytokine signaling; immunotherapy; metastasis; NK cells

Indexed keywords

CYTOKINE INDUCED SH2 CONTAINING PROTEIN; GAMMA INTERFERON; SUPPRESSOR OF CYTOKINE SIGNALING; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER CONTROL; CARCINOGENESIS; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; FIBROSARCOMA; FLOW CYTOMETRY; IMMUNE RESPONSE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; LYMPHOMA; METASTASIS; MOUSE; MULTIPLE MYELOMA; NATURAL KILLER CELL; NONHUMAN; PROSTATE CARCINOMA; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 85011886955     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1267892     Document Type: Article

References (27)

1. Smyth MJ, Ngiow SF, Ribas A, Teng MW. Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol 2016; 13:143-58; PMID:26598942; http://dx.doi.org/10.1038/nrclinonc.2015.209
2. Munn DH, Bronte V. Immune suppressive mechanisms in the tumor microenvironment. Curr Opin Immunol 2016; 39:1-6; PMID:26609943; http://dx.doi.org/10.1016/j.coi.2015.10.009
3. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015; 373:23-34; PMID:26027431; http://dx.doi.org/10.1056/NEJMoa1504030
4. Martinet L, Smyth MJ. Balancing natural killer cell activation through paired receptors. Nat Rev Immunol 2015; 15:243-54; PMID:25743219; http://dx.doi.org/10.1038/nri3799
5. Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L. Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol 2012; 12:239-52; PMID:22437937; http://dx.doi.org/10.1038/nri3174
6. Blake SJ, Stannard K, Liu J, Allen S, Yong MC, Mittal D, Aguilera AR, Miles JJ, Lutzky VP, de Andrade LF, et al. Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy. Cancer Discov 2016; 6:446-59; PMID:26787820; http://dx.doi.org/10.1158/2159-8290.CD-15-0944
7. Yoshimura A, Ohkubo T, Kiguchi T, Jenkins NA, Gilbert DJ, Copeland NG, Hara T, Miyajima A. A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. EMBO J 1995; 14:2816-26; PMID:7796808
8. Matsumoto A, Masuhara M, Mitsui K, Yokouchi M, Ohtsubo M, Misawa H, Miyajima A, Yoshimura A. CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood 1997; 89:3148-54; PMID:9129017
9. Aman MJ, Migone TS, Sasaki A, Ascherman DP, Zhu M, Soldaini E, Imada K, Miyajima A, Yoshimura A, Leonard WJ. CIS associates with the interleukin-2 receptor beta chain and inhibits interleukin-2-dependent signaling. J Biol Chem 1999; 274:30266-72; PMID:10514520; http://dx.doi.org/10.1074/jbc.274.42.30266
10. Sathe P, Delconte RB, Souza-Fonseca-Guimaraes F, Seillet C, Chopin M, Vandenberg CJ, Rankin LC, Mielke LA, Vikstrom I, Kolesnik TB, et al. Innate immunodeficiency following genetic ablation of Mcl1 in natural killer cells. Nat Commun 2014; 5:4539; PMID:25119382; http://dx.doi.org/10.1038/ncomms5539
11. Delconte RB KT, Dagley LF, Rautela J, Shi W, Putz EM, Stannard K, Zhang JG, Teh C, Firth M, Ushiki T, et al. CIS is a potent checkpoint in NK cell-mediated tumour immunity. Nat Immunol 2016; 17(7):816-24; PMID:27213690; http://dx.doi.org/10.1038/ni.3470
12. Yang XO, Zhang H, Kim BS, Niu X, Peng J, Chen Y, Kerketta R, Lee YH, Chang SH, Corry DB, et al. The signaling suppressor CIS controls proallergic T cell development and allergic airway inflammation. Nat Immunol 2013; 14:732-40; PMID:23727894; http://dx.doi.org/10.1038/ni.2633
13. Palmer DC, Guittard GC, Franco Z, Crompton JG, Eil RL, Patel SJ, Ji Y, Van Panhuys N, Klebanoff CA, Sukumar M, et al. Cish actively silences TCR signaling in CD8+T cells to maintain tumor tolerance. J Exp Med 2015; 212:2095-113; PMID:26527801; http://dx.doi.org/10.1084/jem.20150304
14. Smyth MJ, Kelly JM, Baxter AG, Korner H, Sedgwick JD. An essential role for tumor necrosis factor in natural killer cell-mediated tumor rejection in the peritoneum. J Exp Med 1998; 188:1611-9; PMID:9802973; http://dx.doi.org/10.1084/jem.188.9.1611
15. Guillerey C, Ferrari de Andrade L, Vuckovic S, Miles K, Ngiow SF, Yong MC, Teng MW, Colonna M, Ritchie DS, Chesi M, et al. Immunosurveillance and therapy of multiple myeloma are CD226 dependent. J Clin Invest 2015; 125:2077-89; PMID:25893601; http://dx.doi.org/10.1172/JCI77181
16. Li S, Chen S, Xu X, Sundstedt A, Paulsson KM, Anderson P, Karlsson S, Sjögren HO, Wang P. Cytokine-induced Src homology 2 protein (CIS) promotes T cell receptor-mediated proliferation and prolongs survival of activated T cells. J Exp Med 2000; 191:985-94; PMID:10727460; http://dx.doi.org/10.1084/jem.191.6.985
17. Gilfillan S, Chan CJ, Cella M, Haynes NM, Rapaport AS, Boles KS, Andrews DM, Smyth MJ, Colonna M. DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J Exp Med 2008; 205:2965-73; PMID:19029380; http://dx.doi.org/10.1084/jem.20081752
18. Allard B, Pommey S, Smyth MJ, Stagg J. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin Cancer Res 2013; 19:5626-35; PMID:23983257; http://dx.doi.org/10.1158/1078-0432.CCR-13-0545
19. Klages K, Mayer CT, Lahl K, Loddenkemper C, Teng MW, Ngiow SF, Smyth MJ, Hamann A, Huehn J, Sparwasser T. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer Res 2010; 70:7788-99; PMID:20924102; http://dx.doi.org/10.1158/0008-5472.CAN-10-1736
20. Ngiow SF, von Scheidt B, Moller A, Smyth MJ, Teng MW. The interaction between murine melanoma and the immune system reveals that prolonged responses predispose for autoimmunity. Oncoimmunology 2013; 2:e23036; PMID:23524369; http://dx.doi.org/10.4161/onci.23036
21. Ferrari de Andrade L, Ngiow SF, Stannard K, Rusakiewicz S, Kalimutho M, Khanna KK, Tey SK, Takeda K, Zitvogel L, Martinet L, Smyth MJ. Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma. Cancer Res 2014; 74:7298-308; PMID:25351955; http://dx.doi.org/10.1158/0008-5472.CAN-14-1339
22. Mlecnik B, Bindea G, Angell HK, Sasso MS, Obenauf AC, Fredriksen T, Lafontaine L, Bilocq AM, Kirilovsky A, Tosolini M, et al. Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. Sci Transl Med 2014; 6:228ra37; PMID:24648340; http://dx.doi.org/10.1126/scitranslmed.3007240
23. de Andrade LF, Ngiow SF, Martinet L, Smyth MJ. Natural Killer cell control of mutant melanoma during targeted therapy. Oncoimmunology 2015; 4:e998119; PMID:26137412; http://dx.doi.org/10.1080/2162402X.2014.998119
24. Guillerey C, Huntington ND, Smyth MJ. Targeting natural killer cells in cancer immunotherapy. Nat Immunol 2016; 17:1025-36; PMID:27540992; http://dx.doi.org/10.1038/ni.3518
25. Souza-Fonseca-Guimaraes F, Young A, Mittal D, Martinet L, Bruedigam C, Takeda K, Andoniou CE, Degli-Esposti MA, Hill GR, Smyth MJ. NK cells require IL-28R for optimal in vivo activity. Proc Natl Acad Sci U S A 2015; 112:E2376-84; PMID:25901316; http://dx.doi.org/10.1073/pnas.1424241112
26. Chan CJ, Martinet L, Gilfillan S, Souza-Fonseca-Guimaraes F, Chow MT, Town L, Ritchie DS, Colonna M, Andrews DM, Smyth MJ. The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. Nat Immunol 2014; 15:431-8; PMID:24658051; http://dx.doi.org/10.1038/ni.2850
27. Guillerey C, Chow MT, Miles K, Olver S, Sceneay J, Takeda K, Möller A, Smyth MJ. Toll-like receptor 3 regulates NK cell responses to cytokines and controls experimental metastasis. Oncoimmunology 2015; 4:e1027468; PMID:26405596; http://dx.doi.org/10.1080/2162402X.2015.1027468